|Home | English version | Mappa | Commenti | Sondaggio | Staff | Contattaci||Cerca nel sito|
|Istituto di scienza dell'alimentazione|
Contributo in atti di convegno
Titolo: Selenium Binding Proteinol and selenium levels as possible predictive markers of progression for hepatocellular carcinoma
Anno di pubblicazione: 2011
Autori: E. Guerriero, F. Capone, M. Accardo, G. Colonna, M. Di Stasio, M.G. Volpe, M. Nazzaro, M. Polimeno, S. Scala, G. Castello, S. Costantini
Affiliazioni autori: 1 Istituto Nazionale Tumori "Fondazione Pasca/e" o Centro Ricerche Oncologiche di Mercogliano, Mercogliano (AV), ltaly 2 Department of Public Health, Section of Pathology, Second University of Naples, Naples, ltaly 3 Department of Biochemistry and Biophysics and CRISCEB - (lnterdepartmenta/ Research Center far Computa tiana/ and Biotechnological Sciences), Second University of Naples, Naples, ltaly 4 1nstitute of Food Sciences -CNR, Avellino, ltaly 5 Istituto Nazionale Tumori "Fondazione Pasca/e ' Naples, ltaly
Abstract: The human selenium binding protein-1 (SELENBP1 ) is expressed in a variety of cells and tissues and was discovered as a protein in the liver that incorporated exogenously administered sodium selenite in vivo. lts reduced expression has been reported for some human cancers. Moreover, the correlation between decreased levels of selenium and increased DNA damage and oxidative stress means the importance of this trace element. In fact, many studies have evidenced its lower serum, plasma and tissue levels in patients with different diseases and cancers. In this work we have eva luated the SELENBPl expression in tissue samples of patients with different malignant grades of hepatocellular carcinoma (HCC) by common immunohistochemistry techniques. Observations at high magnification showed a mild positivity in many hepatocytes of carcinoma of grade l and light and discontinuous positivity in few moderately differentiated hepatocytes of carcinomas of grade Il. In contrast, there was no positivity for hepatocytes in carcinomas of grade 111; in fact, in these cases the hepatocyte population was completely negative for SELENBP1 staining. Moreover, liver selenium concentrations were measured in the same tissue samples by atomic absorption spectrometry. Our results showed that the selenium concentrations decreased when the malignant grade increased. Furthermore a significant correlation between selenium levels and human selenium binding protein-1 (SELENBPl ) down-expression in the liver was found. Therefore, al i the data suggested that i) the evaluation of selenium and SELENBP1 concentrations can particularly be useful for prognosis improvement when cli nica! considerations suggest a hepatic biopsy in cirrhotic patients, and ii) the intake of selenium and its derivatives in cirrhotic patients shou ld be considered as possible drug against HCC in agreement to many studies on human hepatoma cells and on animai models of liver cancers that showed the cytotoxic and antioxidant effects of selenium.
Lingua abstract: inglese
Referee: Ś: Nazionale
Congresso nome: 53th Annual Meeting of the Italian Cancer Society: Back to the Future - Translating cancer research from bedside to bench and back.
Congresso luogo: Torino
Congresso data: 19-22 ottobre 2011
Congresso rilevanza: Internazionale
Congresso relazione: Contributo
|Home | Il CNR | I servizi | News | Eventi | Istituti | Focus|